On April 13, 2026, Travere Therapeutics announced that the FDA approved FILSPARI® for treating FSGS, the first medication approved for this condition, potentially benefiting over 30,000 individuals in the U.S. In clinical trials, FILSPARI reduced proteinuria by 46% compared to 30% for irbesartan, demonstrating its efficacy.